Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Martyna Mieszczak; Marika Pitnoczko; Kinga Obst; Zuzanna Niedziela-Schwartz; Piotr Rakowicz; Maciej Krawczyński; Marcin Stopa

doi:10.5114/ko.2025.152090

POLSKI

eISSN: 2719-3209
ISSN: 0023-2157

Klinika Oczna / Acta Ophthalmologica Polonica

Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2025
vol. 127

Send email

Copy url:

Original article

Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Martyna Mieszczak

¹

,

Marika Pitnoczko

¹

,

Kinga Obst

¹

,

Zuzanna Niedziela-Schwartz

¹

,

Piotr Rakowicz

¹

,

Maciej Krawczyński

^{2, 3}

,

Marcin Stopa

¹

Eye Diseases Clinic, Department of Eye Diseases and Optometry, Poznan University of Medical Sciences, Poland
Department of Medical Genetics, Poznan University of Medical Sciences, Poland
Genesis Medical Genetics Center in Poznan, Poland

KLINIKA OCZNA 2025, 127, 2: 80-86

DOI: https://doi.org/10.5114/ko.2025.152090

Online publish date: 2025/06/23

Article files

- KO-00549_EN.pdf [0.24 MB]

- KO-00549_PL.pdf [0.25 MB]

Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Mieszczak M, Pitnoczko M, Obst K, et al. Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica. 2025;127(2):80-86. doi:10.5114/ko.2025.152090.

APA

Mieszczak, M., Pitnoczko, M., Obst, K., Niedziela-Schwartz, Z., Rakowicz, P.,  & Krawczyński, M. et al. (2025). Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica, 127(2), 80-86. https://doi.org/10.5114/ko.2025.152090

Chicago

Mieszczak, Martyna, Marika Pitnoczko, Kinga Obst, Zuzanna Niedziela-Schwartz, Piotr Rakowicz, Maciej Krawczyński,  and Marcin Stopa. 2025. "Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)". Klinika Oczna / Acta Ophthalmologica Polonica 127 (2): 80-86. doi:10.5114/ko.2025.152090.

Harvard

Mieszczak, M., Pitnoczko, M., Obst, K., Niedziela-Schwartz, Z., Rakowicz, P., Krawczyński, M.,  and Stopa, M. (2025). Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica, 127(2), pp.80-86. https://doi.org/10.5114/ko.2025.152090

MLA

Mieszczak, Martyna et al. "Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 127, no. 2, 2025, pp. 80-86. doi:10.5114/ko.2025.152090.

Vancouver

Mieszczak M, Pitnoczko M, Obst K, Niedziela-Schwartz Z, Rakowicz P, Krawczyński M et al. Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica. 2025;127(2):80-86. doi:10.5114/ko.2025.152090.

PlumX metrics:

1. Colenbrander A. Visual functions and functional vision. Int Congr Ser 2005; 1282: 482-486.

2. Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol 2018; 46: 247-259.

3. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390: 849-860.

4. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.

5. Moiseyev G, Chen Y, Takahashi Y, et al. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 2005; 102: 12413-12418.

6. Jaśkowiak K, Stopa M, Krawczyński M, et al. Inherited retinal dystrophies caused by RPE65 gene mutation: clinical presentation, economic and social burden. Klin Oczna 2022; 124: 7-15.

7. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra15.

8. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A 2005; 102: 6177-6182.

9. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 2016; 388: 661-672.

10. Geruschat DR, Bittner AK, Dagnelie G. Orientation and mobility assessment in retinal prosthetic clinical trials. Optom Vis Sci 2012; 89: 1308-1315.

11. Geruschat DR, Turano KA, Stahl JW. Traditional measures of mobility performance and retinitis pigmentosa. Optom Vis Sci 1998; 75: 525-537.

12. Stone EM. Retinal Information Highway: From Photonto Perception – The Proctor Lecture. Invest Ophthalmol Vis Sci 2007; 48: 4848-4861.

13. Soong GP, Lovie-Kitchin JE, Brown B. Does the mobility performance of visually impaired adults improve immediately after orientation and mobility training? Optom Vis Sci 2001; 78: 657-666.

Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Martyna Mieszczak 1 , Marika Pitnoczko 1 , Kinga Obst 1 , Zuzanna Niedziela-Schwartz 1 , Piotr Rakowicz 1 , Maciej Krawczyński 2, 3 , Marcin Stopa 1

Martyna Mieszczak

¹

,

Marika Pitnoczko

¹

,

Kinga Obst

¹

,

Zuzanna Niedziela-Schwartz

¹

,

Piotr Rakowicz

¹

,

Maciej Krawczyński

^{2, 3}

,

Marcin Stopa

¹